At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 166 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Ipilimumab for Various Advanced Cancer. Completed, enrolled 166 participants across 54 sites in 15 countries.
Detailed Summary
The purpose of this study is to determine the safety and effectiveness of nivolumab alone and in combination with ipilimumab in pediatric patients with high grade primary central nervous system (CNS) malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVarious Advanced Cancer
CountriesAustralia, Brazil, Canada, France, Germany, Hong Kong, Israel, Netherlands, Norway, Poland, Russia, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartJun 2017
Primary CompletionMar 2020
Study CompletionJan 2022
TodayJul 2026
First PostedApr 27, 2017
Enrollment StartJun 12, 2017
Primary CompletionMar 10, 2020
Study CompletionJan 17, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.2 years ago
Interventions
Nivolumabbiological
Specified dose on specified days
Ipilimumabbiological
Specified dose on specified days